High hepatitis B surface antigen levels predict insignificant fibrosis in hepatitis B e antigen positive chronic hepatitis B

PLoS ONE

Volumn 7, Issue 8, 2012, Pages

  Seto, Wai Kay ^a   Wong, Danny Ka Ho ^a   Fung, James ^a   Ip, Philip P C ^a   Yuen, John Chi Hang ^a   Hung, Ivan Fan Ngai ^a   Lai, Ching Lung ^a,b   Yuen, Man Fung ^a,b  

^a UNIVERSITY OF HONG KONG   (Hong Kong)

^b THE UNIVERSITY OF HONG KONG   (Hong Kong)

Author keywords

[No Author keywords available]

Indexed keywords

ALANINE AMINOTRANSFERASE; HEPATITIS B SURFACE ANTIGEN; HEPATITIS B(E) ANTIGEN;

ACCURACY; ADULT; ALANINE AMINOTRANSFERASE BLOOD LEVEL; ARTICLE; CONTROLLED STUDY; DIAGNOSTIC TEST ACCURACY STUDY; DISEASE SEVERITY; FEMALE; HEPATITIS B; HEPATITIS B SURFACE ANTIGEN BLOOD LEVEL; HEPATITIS B VIRUS; HUMAN; HUMAN TISSUE; KNODELL HISTOLOGIC ACTIVITY INDEX; LIVER BIOPSY; LIVER FIBROSIS; LIVER HISTOLOGY; MAJOR CLINICAL STUDY; MALE; PREDICTION; PREDICTIVE VALUE; PROTEIN BLOOD LEVEL; RECEIVER OPERATING CHARACTERISTIC; SENSITIVITY AND SPECIFICITY; STAGING;

ADOLESCENT; ADULT; FEMALE; HEPATITIS B E ANTIGENS; HEPATITIS B SURFACE ANTIGENS; HEPATITIS B, CHRONIC; HUMANS; LIVER CIRRHOSIS; MALE; MIDDLE AGED; MULTIVARIATE ANALYSIS; YOUNG ADULT;

EID: 84865176357     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0043087     Document Type: Article

References (39)

1. Lai CL, Yuen MF, ((2007)) The natural history and treatment of chronic hepatitis B: a critical evaluation of standard treatment criteria and end points. Ann Intern Med 147:: 58--61.
2. Rockey DC, Caldwell SH, Goodman ZD, Nelson RC, Smith AD, ((2009)) Liver biopsy. Hepatology 49:: 1017--1044.
3. Lok AS, McMahon BJ, ((2009)) Chronic hepatitis B: update 2009. Hepatology 50:: 661--662.
4. Liaw YF, Leung N, Kao JH, Piratvisuth T, Gane E, et al. ((2008)) Asian-Pacific consensus statement on the management of chronic hepatitis B: a 2008 update. Hepatol Int 2:: 263--283.
5. European Association For The Study Of The L, ((2012)) EASL Clinical Practice Guidelines: Management of chronic hepatitis B virus infection. J Hepatol 57:: 167--185.
6. Yuen MF, Yuan HJ, Wong DK, Yuen JC, Wong WM, et al. ((2005)) Prognostic determinants for chronic hepatitis B in Asians: therapeutic implications. Gut 54:: 1610--1614.
7. Andreani T, Serfaty L, Mohand D, Dernaika S, Wendum D, et al. ((2007)) Chronic hepatitis B virus carriers in the immunotolerant phase of infection: histologic findings and outcome. Clin Gastroenterol Hepatol 5:: 636--641.
8. Kumar M, Sarin SK, Hissar S, Pande C, Sakhuja P, et al. ((2008)) Virologic and histologic features of chronic hepatitis B virus-infected asymptomatic patients with persistently normal ALT. Gastroenterology 134:: 1376--1384.
9. Seto WK, Lai CL, Ip PP, Fung J, Wong DK, et al. ((2012)) A large population histology study showing the lack of association between ALT elevation and significant fibrosis in chronic hepatitis B. PLoS One. 7:: e32622.
10. Prati D, Taioli E, Zanella A, Della Torre E, Butelli S, et al. ((2002)) Updated definitions of healthy ranges for serum alanine aminotransferase levels. Ann Intern Med 137:: 1--10.
11. Lee JK, Shim JH, Lee HC, Lee SH, Kim KM, et al. ((2010)) Estimation of the healthy upper limits for serum alanine aminotransferase in Asian populations with normal liver histology. Hepatology 51:: 1577--1583.
12. Zeng MD, Lu LG, Mao YM, Qiu DK, Li JQ, et al. ((2005)) Prediction of significant fibrosis in HBeAg-positive patients with chronic hepatitis B by a noninvasive model. Hepatology 42:: 1437--1445.
13. Fung J, Lai CL, Fong DY, Yuen JC, Wong DK, et al. ((2008)) Correlation of liver biochemistry with liver stiffness in chronic hepatitis B and development of a predictive model for liver fibrosis. Liver Int 28:: 1408--1416.
14. Seto WK, Lee CF, Lai CL, Ip PP, Fong DY, et al. ((2011)) A new model using routinely available clinical parameters to predict significant liver fibrosis in chronic hepatitis B. PLoS One. 6:: e23077.
15. Myers RP, Tainturier MH, Ratziu V, Piton A, Thibault V, et al. ((2003)) Prediction of liver histological lesions with biochemical markers in patients with chronic hepatitis B. J Hepatol. 39:: 222--230.
16. Wai CT, Cheng CL, Wee A, Dan YY, Chan E, et al. ((2006)) Non-invasive models for predicting histology in patients with chronic hepatitis B. Liver Int. 26:: 666--672.
17. Fung J, Lai CL, Seto WK, Yuen MF, ((2011)) The use of transient elastography in the management of chronic hepatitis B. Hepatol Int. 5:: 868--875.
18. Fung J, Lai CL, Yuen MF, ((2010)) Hepatitis B virus DNA and hepatitis B surface antigen levels in chronic hepatitis B. Expert Rev Anti Infect Ther. 8:: 717--726.
19. Brunetto MR, Oliveri F, Colombatto P, Moriconi F, Ciccorossi P, et al. ((2010)) Hepatitis B surface antigen serum levels help to distinguish active from inactive hepatitis B virus genotype D carriers. Gastroenterology 139:: 483--490.
20. Wiegand J, Wedemeyer H, Finger A, Heidrich B, Rosenau J, et al. ((2008)) A decline in hepatitis B virus surface antigen (hbsag) predicts clearance, but does not correlate with quantitative hbeag or HBV DNA levels. Antivir Ther 13:: 547--554.
21. Tseng TC, Liu CJ, Su TH, Wang CC, Chen CL, et al. (2011) Serum hepatitis B surface antigen levels predict surface antigen loss in hepatitis B e antigen seroconverters. Gastroenterology 141: 517-525, 525 e511-512.
22. Seto WK, Wong DK, Fung J, Hung IF, Fong DY, et al. (2012) A large case-control study on the predictability of hepatitis B surface antigen (HBsAg) levels three years before HBsAg seroclearance. Hepatology.
23. Moucari R, Mackiewicz V, Lada O, Ripault MP, Castelnau C, et al. ((2009)) Early serum HBsAg drop: a strong predictor of sustained virological response to pegylated interferon alfa-2a in HBeAg-negative patients. Hepatology 49:: 1151--1157.
24. Chan HL, Wong VW, Wong GL, Tse CH, Chan HY, et al. ((2010)) A longitudinal study on the natural history of serum hepatitis B surface antigen changes in chronic hepatitis B. Hepatology. 52:: 1232--1241.
25. Jaroszewicz J, Calle Serrano B, Wursthorn K, Deterding K, Schlue J, et al. ((2010)) Hepatitis B surface antigen (HBsAg) levels in the natural history of hepatitis B virus (HBV)-infection: a European perspective. J Hepatol 52:: 514--522.
26. Chan HL, Thompson A, Martinot-Peignoux M, Piratvisuth T, Cornberg M, et al. ((2011)) Hepatitis B surface antigen quantification: why and how to use it in 2011- a core group report. J Hepatol 55:: 1121--1131.
27. Ishak K, Baptista A, Bianchi L, Callea F, De Groote J, et al. ((1995)) Histological grading and staging of chronic hepatitis. J Hepatol 22:: 696--699.
28. Knodell RG, Ishak KG, Black WC, Chen TS, Craig R, et al. ((1981)) Formulation and application of a numerical scoring system for assessing histological activity in asymptomatic chronic active hepatitis. Hepatology 1:: 431--435.
29. Mani H, Kleiner DE, ((2009)) Liver biopsy findings in chronic hepatitis B. Hepatology. 49:: S61--71.
30. Colloredo G, Bellati G, Sonzogni A, Zavaglia C, Fracassetti O, et al. ((1999)) Semiquantitative assessment of IgM antibody to hepatitis B core antigen and prediction of the severity of chronic hepatitis B. J Viral Hepat. 6:: 429--434.
31. Martinot-Peignoux M, Carvalho-Filho R, Ferreira Netto Cardoso AC, Lapalus M, Lada O, et al. ((2012)) Significant genotype-specific association of hepatitis B surface antigen level and severity of liver disease in patients with chronic hepatitis B (abstract). J Hepatol 56:: S211.
32. Nguyen T, Thompson AJ, Bowden S, Croagh C, Bell S, et al. ((2010)) Hepatitis B surface antigen levels during the natural history of chronic hepatitis B: a perspective on Asia. J Hepatol 52:: 508--513.
33. Yuen MF, Ng IO, Fan ST, Yuan HJ, Wong DK, et al. ((2004)) Significance of HBV DNA levels in liver histology of HBeAg and Anti-HBe positive patients with chronic hepatitis B. Am J Gastroenterol. 99:: 2032--2037.
34. Yuen MF, Chow DH, Tsui K, Wong BC, Yuen JC, et al. ((2005)) Liver histology of Asian patients with chronic hepatitis B on prolonged lamivudine therapy. Aliment Pharmacol Ther 21:: 841--849.
35. Pollicino T, Amaddeo G, Restuccia A, Raffa G, Alibrandi A, et al. (2012) Impact of hepatitis B virus (HBV) preS/S genomic variability on HBV surface antigen and HBV DNA serum levels. Hepatology.
36. Chen CJ, Lee MH, Liu J, Batrla-Utermann R, Jen CL, et al. ((2011)) Quantitative serum levels of hepatitis B virus DNA and surface antigen are indepedent risk predictors of hepatocellular carcinoma (abstract). Hepatology 54:: 881A.
37. Tseng TC, Liu CJ, Yang HC, Su TH, Wang CC, et al. (2012) High levels of hepatitis B surface antigen increase risk of hepatocellular carcinoma in patients with low HBV load. Gastroenterology 142: 1140-1149 e1143; quiz e1113-1144.
38. Sumi H, Yokosuka O, Seki N, Arai M, Imazeki F, et al. ((2003)) Influence of hepatitis B virus genotypes on the progression of chronic type B liver disease. Hepatology 37:: 19--26.
39. Yuen MF, Tanaka Y, Ng IO, Mizokami M, Yuen JC, et al. ((2005)) Hepatic necroinflammation and fibrosis in patients with genotypes Ba and C, core-promoter and precore mutations. J Viral Hepat 12:: 513--518.